Clinical TrialJun 22, 2026, 07:31 AM
BridgeBio to present positive Phase 3 infigratinib data at ICCBH
AI Summary
BridgeBio Pharma announced it will present additional positive data from its PROPEL 3 global Phase 3 pivotal study of oral infigratinib for children with achondroplasia at the International Congress of Children’s Bone Health (ICCBH) 2026. The company will also share an oral presentation and four posters covering quality of life, early intervention research, observational study findings, and educational resources for achondroplasia. Additionally, a poster on autosomal dominant hypocalcemia type 1 (ADH1) findings from its CLARIFY disease monitoring study will be presented.
Key Highlights
- Additional positive data from PROPEL 3 Phase 3 study of infigratinib to be presented.
- Late-breaking oral presentation on infigratinib in achondroplasia at ICCBH.
- Oral presentation on Health-Related Quality of Life from PROPEL study.
- Four posters on achondroplasia research and educational resources.
- Poster on ADH1 findings from CLARIFY disease monitoring study.
Price Impact
More from BBIO